India Begins First CAR-T Therapy Manufacturing Training

India has achieved a great step forward in the production of CAR-T therapy with the introduction of the first hands-on cell and gene therapy training course.

The collaboration between Miltenyi Biotec, the Translational Health Science and Technology Institute (THSTI) and BIRAC resulted in the program.

The three-day workshop was carried out in the framework of NCR Biotech Science Cluster at THSTI between November 12-14, 2025. It incorporates online courses at Miltenyi University with practical courses on pre-clinical development, closed-system manufacturing, quality control, and clinical translation.

Also Read: Bridging Collaboration Gaps to Boost India's Pharma Discovery

According to Prof. G. Karthikeyan, the Executive Director of BRIC–THSTI, the initiative is a big leap towards reinforcing the ecosystem of translational research in India. Dr. Jitendra Kumar, the Managing Director of BIRAC, further stated that BIRAC is still determined to produce the skilled talent required to be able to access high-level therapies.

Since the world is increasingly in need of CAR-T manufacturing, this partnership gives India a better opportunity to improve its translational capacity, expand the domestic manufacturing industry, and emerge as an important center in the global cell and gene-therapy market.

The members of the group receive a practical exposure to the advanced Miltenyi equipment, such as the CliniMACS Prodigy and MACSQuant Analyzer, and they can still tap into the virtual learning center of the company.

According to Dr. Priya Kapoor G. Hingorani, Managing Director of Miltenyi Biotec India, we are investing in the next-generation of scientists in India, which means that the advanced therapies would be able to make the transition into the patient locally, in a relevant and sustainable manner through our collaboration with THSTI and BIRAC.